The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms

Nature Reviews Cancer

Volumn 6, Issue 3, 2006, Pages 240-248

  Antoni, Michael H ^a   Lutgendorf, Susan K ^b   Cole, Steven W ^c   Dhabhar, Firdaus S ^d   Sephton, Sandra E ^e   McDonald, Paige Green ^f   Stefanek, Michael ^f   Sood, Anil K ^g  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; AUTACOID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; INDOMETACIN; ISOPRENALINE; LITHIUM; MELATONIN; MONOAMINE OXIDASE INHIBITOR; OXYTOCIN ANTAGONIST; PROPRANOLOL; TRICYCLIC ANTIDEPRESSANT AGENT; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B CELL LYMPHOMA; BEHAVIOR; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CHRONIC DISEASE; CIRCADIAN RHYTHM; COMPREHENSION; DEPRESSION; HEALTH BEHAVIOR; HUMAN; KAPOSI SARCOMA; LUNG METASTASIS; MENTAL STRESS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RECTUM CARCINOMA; REVIEW; SOCIAL SUPPORT; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; WART VIRUS;

ANIMALS; DEPRESSION; HUMANS; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; SOCIAL SUPPORT; SOCIOECONOMIC FACTORS; STRESS, PSYCHOLOGICAL;

EID: 33644526932     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1820     Document Type: Review

References (146)

1. Stefanek, M. & McDonald, P. G. in Handbook of Behavioral Science and Cancer (eds Miller, S. M., Bowen, D. J., Croyle, R. T. & Rowland, J.) (American Psychological Association, Washington DC) (in the press).
2. Reiche, E. M., Nunes, S. O. & Morimoto, H. K. Stress, depression, the immune system, and cancer. Lancet Oncol. 5, 617-625 (2004).
3. Spiegel, D. & Giese-Davis, J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 54, 269-282 (2003).
4. Price, M. A. et al. The role of psychosocial factors in the development of breast carcinoma: part I. The cancer prone personality. Cancer 91, 679-685 (2001).
5. Lillberg, K. et al. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am. J. Epidemiol. 157, 415-423 (2003).
6. Glaser, R. & Kiecolt-Glaser, J. K. Stress-induced immune dysfunction: implications for health. Nature Rev. Immunol. 5, 243-251 (2005).
7. Chrousos, G. P. & Gold, P. W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267, 1244-1252 (1992).
8. Charmandari, E., Tsigos, C. & Chrousos, G. P. Endocrinology of the stress response. Annu. Rev. Physiol. 67, 259-284 (2005).
9. McEwen, B. S. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology 22, 108-124 (2000).
10. Kiecolt-Glaser, J. K., McGuire, L., Robles, T. F. & Glaser, R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu. Rev. Psychol. 53, 83-107 (2002).
11. McEwen, B. S. Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiol. Aging 23, 921-939 (2002).
12. Sood, A. K. et al. Stress hormone mediated invasion of ovarian cancer cells. Clin. Cancer Res. 12, 369-375 (2006).
13. Badino, G. R., Novelli, A., Girardi, C. & Di Carlo, F. Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cell. Pharm. Res. 33, 255-260 (1996).
14. Vandewalle, B., Revillion, F. & Lefebvre, J. Functional β-adrenergic receptors in breast cancer cells. J. Cancer Res. Clin. Oncol. 116, 303-306 (1990).
15. Marchetti, B., Spinola, P. G., Pelletier, G. & Labri, F. A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of &-adrenergic receptors and correlation with tumor growth. J. Steroid Biochem. Mol. Biol. 38, 307-320 (1991).
16. Penninx, B. W. et al. Chronically depressed mood and cancer risk in older persons. J. Natl Cancer Inst. 90, 1888-1893 (1998).
17. Reynolds, P. & Kaplan, G. A. Social connections and risk for cancer: prospective evidence from the Alameda County Study. Behav. Med. 16, 101-110 (1990).
18. Allison, P. J., Guichard, C., Fung, K. & Gilain, L. Dispositional optimism predicts survival status 1 year after diagnosis in head and neck cancer patients. J. Clin. Oncol. 21, 543-548 (2003).
19. Gotay, C. C. Behavior and cancer prevention. J. Clin. Oncol. 23, 301-310 (2005).
20. Laconi, E. et al. Early exposure to restraint stress enhances chemical carcinogenesis in rat liver. Cancer Lett. 161, 215-220 (2000).
21. Ben-Eliyahu, S., Yirmiya, R., Liebeskind, J. C., Taylor, A. N. & Gale, R. P. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav. Immun. 5, 193-205 (1991).
22. Ben-Eliyahu, S., Page, G. G., Yirmiya, R. & Shakhar, G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int. J. Cancer 80, 880-888 (1999).
23. Page, G. G. & Ben-Eliyahu, S. A role for NK cells in greater susceptibility of young rats to metastatic formation. Dev. Comp. Immunol. 23, 87-96 (1999).
24. Page, G. G., Ben-Eliyahu, S., Yirmiya, R. & Liebeskind, J. C. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 54, 21-28 (1993).
25. Stefanski, V. & Ben-Eliyahu, S. Social confrontation and tumor metastasis in rats: defeat and β-adrenergic mechanisms. Physiol. Behav. 60, 277-282 (1996).
26. Ben-Eliyahu, S. et al. The NMDA receptor antagonist MK-801 blocks nonopioid stress induced analgesia and decreases tumor metastasis in the rat. Proc. West. Pharmacol. Soc. 36, 293-298 (1993).
27. Melamed, R. et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 19, 114-126 (2005).
28. Fischman, H. K., Pero, R. W. & Kelly, D. D. Psychogenic stress induces chromosomal and DNA damage. Int. J. Neurosci. 84, 219-227 (1996).
29. Sacharczuk, M., Jaszczak, K. & Sadowski, B. Chromosomal NOR activity in mice selected for high and low swim stress-induced analgesia. Behav. Genet. 33, 435-441 (2003).
30. Thaker, P. H. et al. in The 36th Annual Meeting of the Society of Gynecologic Oncologists 30 (Miami, Florida, 2005).
31. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25 (1997).
32. Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878-4886 (2003).
33. Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996).
34. Lutgendorf, S. K. et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 95, 808-815 (2002).
35. Costanzo, E. S. et al. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104, 305-313 (2005).
36. Fredriksson, J. M., Lindquist, J. M., Bronnikov, G. E. & Nedergaard, J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor-cAMP-protein kinase A pathway involving Src but independently of Erk1/2. J. Biol. Chem. 275, 13802-13811 (2000).
37. Lutgendorf, S. K. et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 9, 4514-4521 (2003).
38. Masur, K., Niggemann, B., Zanker, K. S. & Entschladen, F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β-blockers. Cancer Res. 61, 2866-2869 (2001).
39. McDonald, P. H. & Lefkowitz, R. J. β-Arrestins: new roles in regulating heptahelical receptors' functions. Cell Signal. 13, 683-689 (2001).
40. Abramovitch, R. et al. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 64, 1338-1346 (2004).
41. Lang, K. et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer 112, 231-238 (2004).
42. Jean, D. & Bar-Eli, M. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem. 212, 19-28 (2000).
43. de Rooij, J. et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396, 474-477 (1998).
44. 4 integrin. J. Biol. Chem. 279, 44889-44896 (2004).
45. Distelhorst, C. W. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 9, 6-19 (2002).
46. Herr, I. et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 63, 3112-3120 (2003).
47. Wu, W. et al. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 64, 1757-1764 (2004).
48. Nakane, T. et al. Effects of IL-1 and cortisol on β-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J. Immunol. 145, 260-266 (1990).
49. Dave, J. R. et al. Chronic sustained stress increases levels of anterior pituitary prolactin mRNA. Pharmacol. Biochem. Behav. 67, 423-431 (2000).
50. Almeida, S. A., Petenusci, S. O., Franci, J. A., Rosa e Silva, A. A. & Carvalho, T. L. Chronic immobilization-induced stress increases plasma testosterone and delays testicular maturation in pubertal rats. Andrologia 32, 7-11 (2000).
51. Young, W. S. 3rd & Lightman, S. L. Chronic stress elevates enkephalin expression in the rat paraventricular and supraoptic nuclei. Brain Res. Mol. Brain Res. 13, 111-117 (1992).
52. Clevenger, C. V., Furth, P. A., Hankinson, S. E. & Schuler, L. A. The role of prolactin in mammary carcinoma. Endocr. Rev. 24, 1-27 (2003).
53. Pequeux, C. et al. Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr. Relat. Cancer 11, 871-885 (2004).
54. Pequeux, C. et al. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Cancer Res. 62, 4623-4629 (2002).
55. Chakroborty, D. et al. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 10, 4349-4356 (2004).
56. Basu, S. et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Med. 7, 569-574 (2001).
57. Sephton, S. & Spiegel, D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav. Immun. 17, 321-328 (2003).
58. Sephton, S. E., Sapolsky, R. M., Kraemer, H. C. & Spiegel, D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl Cancer Inst. 92, 994-1000 (2000).
59. Chrousos, C. P. & Gold, P. W. A healthy body in a healthy mind - and vice versa - the damaging power of "uncontrollable" stress. J. Clin. Endocrinol. Metab. 83, 1842-1845 (1998).
60. Filipski, E. et al. Host circadian clock as a control point in tumor progression. J. Natl Cancer Inst. 94, 690-697 (2002).
61. Schernhammer, E. S. et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J. Natl Cancer Inst. 95, 825-828 (2003).
62. Fu, L. & Lee, C. C. The circadian clock: pacemaker and tumour suppressor. Nature Rev. Cancer 3, 350-361 (2003).
63. Fu, L., Pelicano, H., Liu, J., Huang, P. & Lee, C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111, 41-50 (2002).
64. Mormont, M. C. & Levi, F. Circadian-system alterations during cancer processes: a review. Int. J. Cancer 70, 241-247 (1997).
65. Mormont, M. C. et al. Marked 24-h-rest-activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6, 3038-3045 (2000).
66. Kronfol, Z., Nair, M., Zhang, Q., Hill, E. E. & Brown, M. B. Circadian immune measures in healthy volunteers: relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Psychosom. Med. 59, 42-50 (1997).
67. Rich, T. et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 11, 1757-1764 (2005).
68. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
69. Blask, D. E., Sauer, L. A. & Dauchy, R. T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2, 113-132 (2002).
70. Sanchez-Barcelo, E. J., Cos, S., Fernandez, R. & Mediavilla, M. D. Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer 10, 153-159 (2003).
71. Jensen, M. M. The influence of stress on murine leukemia virus infection. Proc. Soc. Exp. Biol. Med. 127, 610-614 (1968).
72. Justice, A. Review of the effects of stress on cancer in laboratory animals: importance of time of stress application and type of tumor. Psychol. Bull. 98, 108-138 (1985).
73. Riley, V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science 212, 1100-1109 (1981).
74. Rowse, G. L., Weinberg, J., Bellward, G. D. & Emerman, J. T. Endocrine mediation of psychosocial stressor effects on mouse mammary tumor growth. Cancer Lett. 65, 85-93 (1992).
75. Romero, L. et al. A possible mechanism by which stress accelerates growth of virally-derived tumors. Proc. Natl Acad. Sci. USA 89, 11084-11087 (1992).
76. McGrath, C. M., Prass, W. A., Maloney, T. M. & Jones, R. F. Induction of endogenous mammary tumor virus expression during hormonal induction of mammary adenoacanthomas and carcinomas of BALB/c female mice. J. Natl Cancer Inst. 67, 841-852 (1981).
77. zur Hausen, H. Viruses in human cancers. Science 254, 1167-1173 (1991).
78. Glaser, R. et al. Stress-related activation of Epstein-Barr virus. Brain Behav. Immun. 5, 219-232 (1991).
79. Stowe, R. P., Pierson, D. L. & Barrett, D. T. Elevated stress hormone levels relate to Epstein-Barr Virus reactivation in astronauts. Psychosom. Med. 63, 891-895 (2001).
80. Cacioppo, J. T. et al. Autonomic and glucocorticoid associations with the steady-state expression of latent Epstein-Barr Virus. Horm. Behav. 42, 32-41 (2002).
81. Glaser, R., Kutz, L. A., MacCallum, R. C. & Malarkey, W. B. Hormonal modulation of Epstein-Barr virus replication. Neuroendocrinology 62, 356-361 (1995).
82. Bromberg-White, J. L. & Meyers, C. Comparison of the basal and glucocorticoid-inducible activities of the upstream regulatory regions of HPV18 and HPV31 in multiple epithelial cell lines. Virology 306, 197-202 (2003).
83. Mittel, R., Pater, A. & Pater, M. M. Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA-protein interactions. J. Virol. 67, 5656-5659 (1993).
84. Gloss, B. et al. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J. 6, 3735-3743 (1987).
85. Pater, M. M., Hughes, G. A., Hyslop, D. E., Nakshatri, H. & Pater, A. Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 335, 832-835 (1988).
86. Bartholomew, J. S. et al. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells. Cancer Res. 57, 937-942 (1997).
87. Coker, A. L., Bond, S., Madeleine, M. M., Luchok, K. & Pirisi, L. Psychosocial stress and cervical neoplasia risk. Psychosom. Med. 65, 644-651 (2003).
88. Pereira, D. B. et al. Life stress and cervical squamous intraepithelial lesions in women with human papillomavirus and human immunodeficiency virus. Psychosom. Med. 65, 427-434 (2003).
89. Pater, M. M. & Pater, A. RU486 inhibits glucocorticoid hormone-dependent oncogenesis by human papillomavirus type 16 DNA. Virology 183, 799-802 (1991).
90. Chou, C. K., Wang, L. H., Lin, H. M. & Chi, C. W. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 16, 13-18 (1992).
91. Kamradt, M. C., Mohideen, N. & Vaughan, A. T. RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol. Oncol. 77, 177-182 (2000).
92. Tur-Kaspa, R., Burk, R. D., Shaul, Y. & Shafritz, D. A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl Acad. Sci. USA 83, 1627-1631 (1986).
93. Chayama, K. et al. A pilot study of corticosteroid priming for lymphoblastoid interferon α in patients with chronic hepatitis C. Hepatology 23, 953-957 (1996).
94. Magy, N. et al. Effects of corticosteroids on HCV infection. Int. J. Immunopharmacol. 21, 253-261 (1999).
95. Yokosuka, O. Role of steroid priming in the treatment of chronic hepatitis B. J. Gastroenterol. Hepatol. 15, E41-E45 (2000).
96. Cole, S. W. et al. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc. Natl Acad. Sci. USA 98, 12695-12700 (2001).
97. Cole, S. W., Jamieson, B. D. & Zack, J. A. cAMP externalizes lymphocyte CXCR4: implications for chemotaxis and HIV infection. J. Immunol. 162, 1392-1400 (1999).
98. Cole, S. W., Korin, Y. D., Fahey, J. L. & Zack, J. A. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J. Immunol. 161, 610-616 (1998).
99. Killebrew, D. & Shiramizu, B. Pathogenesis of HIV-associated non-Hodgkin lymphoma. Curr. HIV Res. 2, 215-221 (2004).
100. Chang, M. et al. β Adrenoreceptors reactivate Kaposi's Sarcoma-associated Herpesvirus lytic replication via PKA-dependent control of viral RTA. J. Virol. 79, 13538-13547 (2005).
101. Turgeman, H. & Aboud, M. Evidence that protein kinase A activity is required for the basal and tax-stimulated transcriptional activity of human T-cell leukemia virus type-Hong terminal repeat. FEBS Lett. 428, 183-187 (1998).
102. Marsland, A. L., Cohen, S., Rabin, B. S. & Manuck, S. B. Associations between stress, trait negative affect, acute immune reactivity, and antibody response to hepatitis B injection in healthy young adults. Health Psychol. 20, 4-11 (2001).
103. Glaser, R. et al. Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosom. Med. 54, 22-29 (1992).
104. Kinzler, K. W. & Vogelstein, B. The Genetic Basis of Human Cancer (McGraw-Hill, Toronto, 1998).
105. Dhabhar, F. S. & McEwen, B. S. Acute stress enhances while chronic stress suppresses cell-mediated immunity in vivo: a potential role for leukocyte trafficking. Brain Behav. Immun. 11, 286-306 (1997).
106. Elenkov, I. J. Systemic stress-induced Th2 shift and its clinical implications. Int. Rev. Neurobiol. 52, 163-186 (2002).
107. Glaser, R. et al. Evidence forashift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. J. Gerontol. A Biol. Sci. Med. Sci. 56, M477-M482 (2001).
108. Felten, S. & Felten, D. in Psychoneuroimmunology (eds Ader, R., Felten, D. & Cohen, N.) 27-71 (St. Louis, Montana, 1991).
109. Dhabhar, F. S. & McEwen, B. S. Stress-induced enhancement of antigen-specific cell-mediated immunity. J. Immunol. 156, 2608-2615 (1996).
110. Saul, A. N. et al. Chronic stress and susceptibility to skin cancer. J. Natl Cancer Inst. 97, 1760-1767 (2005).
111. Kalinichenko, V. V., Mokyr, M. B., Graf, L. H. Jr, Cohen, R. L. & Chambers, D. A. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a β-adrenergic receptor mechanism and decreased TNF-α gene expression. J. Immunol. 163, 2492-2499 (1999).
112. Cook-Mills, J. M., Cohen, R. L., Perlman, R. L. & Chambers, D. A. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology 85, 544-549 (1995).
113. Cook-Mills, J. M., Mokyr, M. B., Cohen, R. L., Perlman, R. L. & Chambers, D. A. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma. Cancer Immunol. Immunother. 40, 79-87 (1995).
114. Shi, Y. et al. Stressed to death: implication of lymphocyte apoptosis for psychoneuroimmunology. Brain Behav. Immun. 17 (Suppl.), S18-S26 (2003).
115. Pollock, R. E., Lotzova, E. & Stanford, S. D. Mechanism of surgical stress impairment of human perioperative natural killer cell cytotoxicity. Arch. Surg. 126, 338-342 (1991).
116. Andersen, B. L. et al. Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst. 90, 30-36 (1998).
117. Lutgendorf, S. K. et al. Social support, distress, and natural killer cell activity in ovarian cancer patients. J. Clin. Oncol. 23, 7106-7113 (2005).
118. Levy, S. M. et al. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom. Med. 52, 73-85 (1990).
119. McGregor, B. A. et al. Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer. J. Psychosom. Res. 56, 1-8 (2004).
120. Sephton, S., Koopman, C., Schaal, M., Thoresen, C. & Spiegel, D. Spiritual expression and immune status in women with metastatic breast cancer: an exploratory study. Breast J. 7, 345-353 (2001).
121. Christie, W. & Moore, C. The impact of humor on patients with cancer. Clin. J. Oncol. Nurs. 9, 211-218 (2005).
122. Antoni, M. H. Stress management effects on psychological, endocrinological, and immune functioning in men with HIV infection: empirical support for a psychoneuroimmunological model. Stress 6, 173-188 (2003).
123. Carlson, L. E., Speca, M., Patel, K. D. & Goodey, E. Mindful ness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 29, 448-474 (2004).
124. Andersen, B. L. et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J. Clin. Oncol. 22, 3570-3580 (2004).
125. Lekander, M., Furst, C. J., Rotstein, S., Blomgren, H. & Fredrikson, M. Social support and immune status during and after chemotherapy for breast cancer. Acta Oncol. 35, 31-37 (1996).
126. Fawzy, F. I., Canada, A. L. & Fawzy, N. W. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch. Gen. Psychiatry 60, 100-103 (2003).
127. Esterling, B. A. et al. Psychosocial modulation of antibody to Epstein-Barr viral capsid antigen and human herpesvirus type-6 in HIV-1-infected and at-risk gay men. Psychosom. Med. 54, 354-371 (1992).
128. Antoni, M. H. et al. Randomized clinical trial of cognitive behavioral stress management on HIV viral load in gay men treated with HAART. Psychosom. Med. (in the press).
129. Antoni, M. H. et al. Increases in a marker of immune system reconstitution are predated by decreases in 24-hour urinary cortisol output and depressed mood during a 10-week stress management intervention in symptomatic gay men. J. Psychosom. Res. 58, 3-13 (2005).
130. Carlson, L. E., Speca, M., Patel, K. D. & Goodey, E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom. Med. 65, 571-581 (2003).
131. Fawzy, F. I. et al. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch. Gen. Psychiatry 47, 729-735 (1990).
132. Spiegel, D., Bloom, J. R., Kraemer, H. C. & Gottheil, E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2, 888-891 (1989).
133. Goodwin, P. J. et al. The effect of group psychosocial support on survival in metastatic breast cancer. N. Engl. J. Med. 345, 1719-1726 (2001).
134. Spiegel, D. Effects of psychotherapy on cancer survival. Nature Rev. Cancer 2, 383-389 (2002).
135. Perron, L., Bairati, I., Harel, F. & Meyer, F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15, 535-541 (2004).
136. Algazi, M., Plu-Bureau, G., Flahault, A., Dondon, M. G. & Le, M. G. Could treatments with β-blockers be associated with a reduction in cancer risk? Rev. Epidemiol. Sante Publique 52, 53-65 (2004) (in French).
137. Li, C. I. et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98, 1504-1513 (2003).
138. Meier, C. R., Derby, L. E., Jick, S. S. & Jick, H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch. Intern. Med. 160, 349-353 (2000).
139. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
140. Lieb, J. Antidepressants, eicosanoids and the prevention and treatment of cancer. A review. Prostaglandins Leukot. Essent. Fatty Acids 65, 233-239 (2001).
141. Sapolsky, R. M. Why Zebras Don't Get Ulcers: A Guide to Stress, Stress-Related Diseases, and Coping (Freeman, New York, 1994).
142. Buchschacher, G. L. J. & Wong-Staal, F. in Cancer: Principles and Practice of Oncology (eds DeVita, V. T. J., Hellman, S. & Rosenberg, S. A.) 165-172 (Lippincott Williams & Wilkins, Philadelphia, 2005).
143. Howley, P. M., Ganem, D. & Kieff, E. in Cancer: Principles and Practice of Oncology (eds De Vita, V. T. J., Hellman, S. & Rosenberg, S. A.) 173-184 (Lippincott Williams & Wilkins, Philadelphia, 2005).
144. Steplewski, Z., Vogel, W. H., Ehya, H., Poropatich, C. & Smith, J. M. Effects of restraint stress on inoculated tumor growth and immune response in rats. Cancer Res. 45, 5128-5133 (1985).
145. Teunis, M. A. et al. Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J. 16, 1465-1467 (2002).
146. Palermo-Neto, J., de Oliveira Massoco, C. & Robespierre de Souza, W. Effects of physical and psychological stressors on behavior, macrophage activity, and Ehrlich tumor growth. Brain Behav. Immun. 17, 43-54 (2003).